Biopsy Market Growth at 11.03% CAGR to Reach USD 76.61 Bn by 2032

Key Highlights

• Biopsy Market size was valued at USD 36.83 Bn in 2025.
• Revenue is expected to reach USD 76.61 Bn by 2032.
• The market is projected to grow at an 11.03% CAGR from 2026 to 2032.
• Tissue biopsy held the largest type share in 2024 and continued its dominant position in 2025.
• Kits & consumables accounted for the largest product type share.
• Cancer dominated the application segment.
• Hospitals held the largest end-user share.
• North America dominated in 2025.
• Asia Pacific is expected to witness the fastest growth.
• Hologic entered a USD 15.4 Bn acquisition agreement with Blackstone and TPG in October 2025.

Why This Matters Now

Cancer diagnosis is moving toward earlier detection, molecular profiling and faster treatment decisions. Hospitals, diagnostic laboratories and device manufacturers now need biopsy systems that improve accuracy without adding patient burden.

Biopsy Market rise from USD 36.83 Bn in 2025 to USD 76.61 Bn by 2032 signals a major shift in oncology infrastructure. The winners will control sampling, imaging, pathology and molecular data workflows.

Market Overview

A biopsy is a medical procedure involving removal of tissue or cells for examination. It is primarily used to detect, diagnose and monitor diseases such as cancer, infections and inflammatory conditions.

Biopsy remains central to cancer confirmation, staging and treatment planning. MMR identifies biopsies as the gold standard for cancer diagnosis, staging and molecular profiling.

Growth is being driven by rising cancer prevalence, demand for minimally invasive diagnostic procedures and advances in imaging-guided technologies. Key innovations include liquid biopsies, AI-assisted diagnostics and robotic-assisted procedures, all of which improve precision and efficiency.

Request Sample Report at : https://www.maximizemarketresearch.com/request-sample/116684/

Key Trends Driving Growth

Cancer burden is the main demand driver. MMR cites WHO data showing cancer remains one of the leading causes of death worldwide, with millions of new cases diagnosed each year and global incidence expected to rise significantly in the coming decade.

Minimally invasive biopsy technologies are changing patient experience. Image-guided biopsy techniques and robotic-assisted procedures can improve diagnostic precision while reducing patient discomfort and recovery time.

Liquid biopsy is the clearest growth opportunity. Unlike invasive tissue biopsies, liquid biopsies use blood or other fluids to analyze biomarkers. This enables early disease detection, treatment monitoring and personalized medicine.

Point-of-care biopsy devices can reduce diagnostic turnaround time. That matters in decentralized and resource-limited settings where delayed diagnosis can delay treatment.

Segment Insights

• Dominant Type Segment: Tissue Biopsy. Tissue biopsy held the largest share in 2024 and continued its dominant position in 2025 because histological confirmation remains the preferred clinical standard for cancer diagnosis and treatment planning.
• Fastest-Growing Segment: Not formally disclosed. The visible MMR page does not identify a formally fastest-growing type, product, application or end-user segment.
• High-Growth Opportunity Signal: Liquid Biopsy. Liquid biopsy is gaining traction because it is minimally invasive and increasingly used in precision oncology and early cancer detection.
• Dominant Product Type: Kits & Consumables. Kits & consumables accounted for the largest share because biopsy needles, reagents and sample collection kits are used repeatedly across biopsy procedures.
• Dominant Application Segment: Cancer. Cancer dominated because biopsy procedures confirm tumor presence, stage disease and guide targeted treatment strategies.
• Dominant End User: Hospitals. Hospitals held the largest share because they perform high biopsy volumes and have imaging systems, pathology laboratories and specialized professionals for complex diagnosis.
• Covered Segments: Tissue Biopsy, Liquid Biopsy, Image-Guided Biopsy, Bone Marrow Biopsy, Needle Biopsy, Surgical Biopsy, Instruments, Kits & Consumables, Services, Cancer, Inflammatory Disorders, Immune Disorders, Peptic Ulcer Disease, Endometriosis and Infectious Diseases.

Regional Growth Story

North America dominated the global Biopsy Market in 2025. The region benefits from high cancer prevalence, strong healthcare infrastructure and rapid adoption of advanced diagnostic technologies.

The United States remains the major contributor. Demand is supported by high healthcare expenditure, cancer screening programs, product approvals and technological innovation in biopsy devices.

Europe held the second-largest share. Germany, the UK and France are named as key countries where cancer awareness, established healthcare systems and minimally invasive biopsy adoption support demand.

Asia Pacific is expected to grow fastest. China, India and Japan are highlighted because healthcare infrastructure is expanding, cancer incidence is rising and demand for early diagnostic procedures is increasing.

Competitive Landscape

The market is highly competitive, with companies using R&D, acquisitions and integrated imaging systems to strengthen position. Key players include Hologic, Leica Biosystems, Mammotome, Becton Dickinson, Medtronic, Johnson & Johnson, Cook Medical, Guardant Health, Exact Sciences, Natera, Roche Diagnostics, QIAGEN, Fujifilm, Olympus, Terumo and Biobot Surgical.

Hologic, BD and Danaher dominate breast biopsy through vacuum-assisted platforms, image-guided systems and marker portfolios. Boston Scientific, Olympus and Cook compete in GI, pulmonary and urology biopsy tools.

Competition is moving toward workflow efficiency, specimen accuracy and integration with imaging modalities. AI-driven targeting and digital pathology connectivity are becoming differentiators as laboratories seek speed and consistency.

Request Sample Report at : https://www.maximizemarketresearch.com/request-sample/116684/

Recent Developments

• Roche Diagnostics inaugurated its Diagnostics Innovation Center in Penzberg, Germany, on 12 February 2026 after a EUR 300 Mn investment. The facility accelerates advanced reagents and diagnostic tests, improving precision tools used in tissue biopsy analysis.
• Fujifilm opened its expanded GBP 400 Mn biomanufacturing facility in Teesside, UK, on 11 February 2026. The expansion improves capacity for therapies that often require biopsy-confirmed diagnostic monitoring.
• BD completed the strategic spin-off of its Biosciences & Diagnostic Solutions segment on 09 February 2026. The separation allows stronger focus on diagnostic and biopsy instrument innovation.
• Leica Biosystems launched Aperio GT 180 DX, CS5 DX scanners and Aperio iQC DX software on 09 December 2025. The platform automates pathology quality control and reduces manual variability in biopsy slide analysis.
• Hologic entered a definitive agreement to be acquired by Blackstone and TPG for about USD 15.4 Bn on 21 October 2025. The transaction gives Hologic financial scale to expand interventional biopsy and diagnostic imaging technologies.
• Exact Sciences acquired exclusive rights to Freenome’s blood-based colorectal cancer screening technology on 06 August 2025. The deal strengthens liquid biopsy capability and expands non-invasive surveillance after tissue biopsy.

Strategic Implications

For hospitals, biopsy capability is becoming a diagnostic-capacity priority. Imaging, pathology, molecular testing and trained specialists must work as one workflow.

For diagnostic laboratories, digital pathology and AI tools can reduce variability and improve throughput. They also require investment in systems and staff training.

For payers, liquid biopsy creates a coverage challenge. MMR states that many insurers cover only single-gene analyses, leaving patients exposed to high out-of-pocket costs for comprehensive multi-gene tests.

For device makers, integrated platforms matter. Companies that connect biopsy instruments, imaging, pathology and molecular diagnostics can defend stronger positions.

Future Outlook

The Biopsy Market is positioned for strong expansion as cancer incidence, screening programs, minimally invasive procedures, liquid biopsy, AI diagnostics, robotic targeting and personalized medicine increase demand. North America leads through healthcare infrastructure and technology adoption, while Asia Pacific grows fastest through expanding access and early diagnosis demand.

Future leaders will combine accurate sampling, digital pathology, liquid biopsy and reimbursement-ready evidence, while laggards will lose share to platforms that reduce diagnostic delay and patient burden.

Related Reports

Global Fluoroscopy Equipment Market: https://www.maximizemarketresearch.com/market-report/global-fluoroscopy-equipment-market/31739/

Global Dengue Testing Market: https://www.maximizemarketresearch.com/market-report/global-dengue-testing-market/107614/

Global Amniotic Membrane Market: https://www.maximizemarketresearch.com/market-report/global-amniotic-membrane-market/30702/

Analyst Perspective

“According to Komal Patil, Research Analyst at Maximize Market Research, ‘The Biopsy Market is projected to grow from USD 36.83 Bn in 2025 to USD 76.61 Bn by 2032 at an 11.03% CAGR, supported by cancer prevalence, minimally invasive diagnosis, image-guided procedures, liquid biopsy and AI-assisted diagnostics. Tissue biopsy leads the visible type structure, while kits and consumables lead product demand. Companies that integrate sampling, pathology and molecular insight will be better positioned.’”

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com